MDNA - Medicenna shares rise on MDNA11 cancer study timeline update

koto_feja/E+ via Getty Images Medicenna Therapeutics (MDNA) said that the initiation of its Phase 1/2 trial of MDNA11 in patients with advanced solid tumors is on track with enrollment set to start in the third quarter of 2021 in Australia. Shares up nearly 9% premarket. The study will also expand into additional sites in the U.S., UK and Canada, the company said. The study, MDNA11-01, includes a monotherapy dose escalation phase followed by expansion phase for both the MDNA11 monotherapy arm at the recommended phase 2 dose ((RP2D)), and a combination arm designed to evaluate MDNA11 with a checkpoint inhibitor. A preliminary update on safety, PK/PD, and biomarker data, from patients enrolled in the dose escalation phase this year, is expected by the end of calendar 2021, and preliminary efficacy updates are expected at various times during calendar 2022. Medicenna had submitted a clinical trial application to a Human Research Ethics Committee ((HREC)) in Australia to initiate a the early-stage trial of MDNA11, last

For further details see:

Medicenna shares rise on MDNA11 cancer study timeline update